Denna webbplats använder cookies för att ditt besök ska fungera bättre.

Vi använder enhetsidentifierare för att med hjälp av Google Analytics analysera vår trafik för att optimera innehållet på denna webbplats. Detta innebär också att vi vidarebefordrar identifierare och annan information från din enhet till Google. Läs mer

Dessa kan i sin tur kombinera informationen med annan information som du har tillhandahållit eller som de har samlat in när du har använt deras tjänster. Vill du inte att information skickas till Google så finns det sätt att blockera detta i din webbläsare. Vi använder även cookies för att förbättra användarupplevelsen. Du kan enkelt ta del av, blockera och avlägsna lagrade cookies om så önskas via inställningar i din webbläsare.

Acceptera alla cookies

A pill from Betagenon to treat life style diseases

The health care and social systems are facing many problems related to the global obesity epidemic and accompanying diseases such as fatty liver, type 2 diabetes, circulatory and cardio vascular problems.

 

An active life style and a restricted calorie intake keep us healthier and feeling better. This is an inspiration to both individuals- when it comes to life style choices, and to researchers- as they study mechanisms where treatments could be developed.

 

AMPK the enzyme at the center of things

At the core of the energy metabolism control system we find the enzyme AMPK (AMP activated protein kinase), which regulates fat metabolism, glucose disposal in muscles and glucose sensing in the insulin regulating β-cells. AMPKs master regulatory function has made it an interesting target from pharmaceutical companies. AMPK also ensures a functional cardiovascular system to promote delivery of nutrients and key regulatory factors to target tissues.

 

As a first company, Betagenon have managed to develop an orally available and safe substance, O304, with promising pre-clinical results. In studies, substance O304 have been able to reduce fatty liver, insulin resistance and improved β-cell function. In an In vitro system, O304 also improved the glucose induced insulin secretion in human islets. O304 also exhibits multiple beneficial effects on the cardiovascular system and is intended to treat both type 2 diabetes and the associated complications.

 

Big Pharma are interested

The Swedish Medical Products Agency (MPA) has approved that Betagenon continue with clinical phase I studies, a process which is carried out in collaboration with an external CRO company. According to Thomas Edlund, CEO at Betagenon the interest for a potential drug with these functions is very large, and Betagenon is in discussions with several Big Pharma.

– We are running a full scale phase I trial involving more than 50 individuals, so that there will be no delays in reaching the market, says Thomas.

 

Read more on
Betagenons site.

 

Text: Karin Borge Renberg

Sök till Uminova Innovation

Vi är alltid på jakt efter fler västerbottniska affärsidéer att boosta. Om du har en, som du tror på och inte kan släppa, så kan du ansöka om vårt affärsstöd. Det tar bara 10 minuter. Vi hör av oss till dig och berättar om och hur vi kan hjälpa dig bäst. Ps. Vi arbetar under full sekretess.